CHINA PHARMA HOLDINGS, INC.
CPHI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CPHI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CPHI
China Pharma Holdings, Inc. (CPHI) is a specialty pharmaceutical company focused on developing, manufacturing, and marketing generic and branded drugs for the Chinese market, with a pipeline of late-stage clinical candidates and a history of operating losses.
Key risk: Going concern uncertainty
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 49 clinical trials · 9 catalysts for CHINA PHARMA HOLDINGS, INC..
China Pharma Holdings, Inc. (CPHI) is a specialty pharmaceutical company focused on developing, manufacturing, and marketing generic and branded drugs for the Chinese market, with a pipeline of late-stage clinical candidates and a history of operating losses.
- Revenue decreased by 10.6% to $1.93 million for the six months ended June 30, 2026, compared to the same period in 2025 [sec_mda · as of 2026-08-14].
- Cash and equivalents were $0.3M as of June 30, 2026 [latest reported financials].
- Net loss was $1.5M for the six months ended June 30, 2026 [latest reported financials].
- The company has a substantial pipeline of Phase 3 trials with topline results expected between December 2026 and June 2029 [upcoming catalysts].
- The company has a going concern qualification and relies on CEO advances for working capital [sec_mda · as of 2026-04-01].
What works
- Revenue from CNS Cerebral & Cardio Vascular products increased 34% to $1.02M for the six months ended June 30, 2026, becoming the largest revenue contributor [sec_mda · as of 2026-08-14].
- The company has multiple Phase 3 registrational trials underway for drugs such as lisaftoclax (APG-2575) and olverembatinib, with topline data expected through 2029 [upcoming catalysts].
- Shareholders' equity stood at $22.7M as of June 30, 2026, providing a capital base to support operations and clinical development [latest reported financials].
What to weigh
- Revenue declined 10.6% year-over-year for the six months ended June 30, 2026, driven by a 42% drop in Anti-Viral/Infection & Respiratory product sales [sec_mda · as of 2026-08-14].
- The company has a going concern qualification, with substantial doubt about its ability to continue as a going concern [sec_mda · as of 2026-04-01].
- Cash and equivalents were only $0.3M as of June 30, 2026, and the company relies on CEO advances and potential debt/equity financing for liquidity [latest reported financials] [sec_mda · as of 2026-04-01].
- Net loss was $1.5M for the six months ended June 30, 2026, with accumulated deficits and ongoing operating losses [latest reported financials].
From the filings
Quoted directly from source documents.
Revenue decreased by 10.6% to $1.93 million for the six months ended June 30, 2026.
“Revenue decreased by 10.6% to $1.93 million for the six months ended June 30, 2026, compared to $2.16 million for the same period in 2025.”
SEC MD&A · August 14, 2026
The company has a going concern qualification.
“This raises substantial doubt about the Company's ability to continue as a going concern.”
SEC MD&A · April 1, 2026
Catalyst timeline
- 2026-12-31 · Phase3_Topline — Topline results from a randomized, double-blind, placebo-controlled Phase III study expected.
- 2027-03-31 · Phase3_Topline · asp2215 — Topline results from a Phase 3 open-label study of ASP2215 versus salvage chemotherapy expected.
- 2027-10-31 · Phase3_Topline · lisaftoclax — Topline results from a global, open-label, randomized Phase 3 registrational study of lisaftoclax (APG-2575) expected.
- 2028-07-01 · Phase3_Topline — Topline results from a Phase III randomized, double-blind, placebo-controlled study expected.
- 2028-08-19 · Phase3_Topline — Topline results from a multi-centre, randomized, placebo-controlled, double-blind trial expected.
- 2028-12-31 · Phase3_Topline · enzalutamide — Topline results from the China ARCHES Phase 3 study of enzalutamide expected.
- 2029-03-26 · Phase3_Topline · apg-2575 — Topline results from a global, multicenter, randomized, double-blind Phase 3 pivotal study of APG-2575 expected.
- 2029-06-30 · Phase3_Topline · olverembatinib — Topline results from a pivotal registrational Phase 3 study of olverembatinib combined with chemotherapy expected.
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Substantial doubt about ability to continue as a going concern [sec_mda · as of 2026-04-01]
- Low cash reserves — Only $0.3M cash as of June 30, 2026, requiring external financing [latest reported financials]
- Revenue decline — Revenue fell 10.6% in H1 2026 vs H1 2025, with key segment dropping 42% [sec_mda · as of 2026-08-14]
- Clinical trial failure risk — Multiple Phase 3 trials may fail, impacting pipeline value and financing [upcoming catalysts]
What to watch
- Phase 3 topline results for multiple candidates starting December 2026, which could significantly impact the company's valuation and financing prospects [upcoming catalysts].
- Ability to secure additional debt or equity financing to address low cash reserves and going concern issues [sec_mda · as of 2026-04-01].
- Revenue trends in CNS/Cardio Vascular and Anti-Viral segments, which are key to near-term financial performance [sec_mda · as of 2026-08-14].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run CHINA PHARMA HOLDINGS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CHINA PHARMA HOLDINGS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
74.5 months
D/E 0.24 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
9 upcoming, next in ~123d
No insider transactions in the last 180 days
Runway
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
4
Total value held
$15K
| Holder | Shares | Value |
|---|---|---|
| citadel advisors llc | 12,924 | $8K |
| renaissance technologies llc | 11,418 | $7K |
| citigroup inc | 996 | $608 |
| danske bank a/s | 1 | $1 |
Short Interest
as of May 20, 2026- % of float
- 0.0%
- Days to cover
- 0.3
- Shares short
- 6,992
- Daily short volume (Jul 8, 2026)
- 4.9%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CPHI short interestGovernance
Frequently asked questions
What is the AI investment thesis for CHINA PHARMA HOLDINGS, INC.?
China Pharma Holdings, Inc. (CPHI) is a specialty pharmaceutical company focused on developing, manufacturing, and marketing generic and branded drugs for the Chinese market, with a pipeline of late-stage clinical candidates and a history of operating losses.
What is CHINA PHARMA HOLDINGS, INC.'s next catalyst?
CHINA PHARMA HOLDINGS, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and" — expected December 31, 2026.
Who is the CEO of CHINA PHARMA HOLDINGS, INC.?
Ms. Zhilin Li is the chief executive officer of CHINA PHARMA HOLDINGS, INC. (CPHI).
Where is CHINA PHARMA HOLDINGS, INC. headquartered?
CHINA PHARMA HOLDINGS, INC. (CPHI) is headquartered in Haikou, China.
What therapeutic areas does CHINA PHARMA HOLDINGS, INC. focus on?
CHINA PHARMA HOLDINGS, INC. develops therapies across Oncology, Immunology, Metabolic, Respiratory, Dermatology, Hematology, Nephrology, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.